logo
Plus   Neg
Share
Email

Stock Alert: Aethlon Medical Surges After FDA Okays Hemopurifier Testing For COVID-19

Shares of Aethlon Medical, Inc. (AEMD) are gaining more than 95 percent or $1.34 in Thursday's morning trade at $2.75.

Thursday, Aethlon Medical said that the FDA has approved a supplement to the company's existing Investigational Device Exemption or IDE for the company's Hemopurifier in viral disease. The approvals allows for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19 in a new feasibility study.

The study, which is the device equivalent of a phase 1 trial, will enroll up to 40 subjects at up to 20 centers in the U.S The Aethlon Hemopurifier is a clinical-stage device designed to combat cancer and life-threatening viral infections. It has previously been tested in patients with hepatitis C virus infection and in one patient with Ebola virus infection.

The stock has traded in a range of $0.76 to $9.00 in the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Editors Pick
Intel Corp's Mobileye and self-driving delivery startup Udelv have signed a deal to launch a fully driverless delivery service in the United States by 2023. The companies plan to produce more than 35,000 Mobileye-driven Transporters by 2028. Domino's Pizza and autonomous vehicle startup Nuro are launching autonomous pizza delivery in Houston, this week. Some Domino's customers in Houston can have a pizza delivered by Nuro's R2 robot. CVS Health is now offering cost COVID-19 vaccines at select CVS Pharmacy locations in four more U.S. states as part of its ongoing effort to expand access to COVID-19 vaccines. It has now expanded the program to 51 more select locations in Arkansas, Nebraska, Iowa and Maine. It began in Washington, West Virginia, Delaware and New Mexico at 15 select locations from March 31.
Follow RTT